Impact of hyperkalaemia definition on incidence assessment: implications for epidemiological research based on a large cohort study in newly diagnosed heart failure patients in primary care

被引:0
作者
Mar Martín-Pérez
Ana Ruigómez
Alexander Michel
Luis A. García Rodríguez
机构
[1] Spanish Centre for Pharmacoepidemiologic Research (CEIFE),
[2] Epidemiology,undefined
[3] Bayer Pharma AG,undefined
来源
BMC Family Practice | / 17卷
关键词
Hyperkalaemia; Heart failure; Incidence; Cohort study; Primary care;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 114 条
[1]  
Nyirenda MJ(2009)Hyperkalaemia BMJ 339 b4114-51
[2]  
Tang JI(2004)Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study N Engl J Med 351 543-4
[3]  
Padfield PL(2003)Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines J Am Coll Cardiol 41 211-11
[4]  
Seckl JR(2008)Hyperkalaemia associated with inhibitors of the renin-angiotensin-aldosterone system: balancing risk and benefit Circulation 118 1609-92
[5]  
Juurlink DN(2004)Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system N Engl J Med 351 585-62
[6]  
Mamdani MM(2009)The frequency of hyperkalemia and its significance in chronic kidney disease Arch Intern Med 169 1156-50
[7]  
Lee DS(2008)Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) Circulation 118 1643-21
[8]  
Kopp A(2011)Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 11-13
[9]  
Austin PC(2012)Predictors of hyperkalemia and death in patients with cardiac and renal disease Am J Cardiol 109 1510-303
[10]  
Laupacis A(2004)How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 10 297-14